Roche buys rights to Evotec drugs

03/10/2009 | Bloomberg

Roche Holding has acquired the rights to a depression drug being developed by German biotech firm Evotec. Roche is also buying back from Evotec the rights to the EVT 100 family of drugs, which includes drugs for Alzheimer's disease and Parkinson's disease.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA